Breaking News

Financial Report: Lilly

July 24, 2014

Patent expirations pummel results

2Q Revenues: $4.9 billion (-17%)

2Q Earnings: $733.5 million (-39%)

YTD Revenues: $9.6 billion (-17%)

YTD Earnings: $1.5 billion (-47%)

Comments: Results were impacted by the loss of U.S. patent exclusivity for Cymbalta, down 73% in the quarter to $401.3 billion, and Evista, down 61% to $108.3 million. Alimta sales were up 6% to $669.4 million. Humalog sales were up 11% to $628.6 million. Cialis sales were up 7% to $567.8 million. Lilly launched Cyramza in the quarter for gastric cancer or gastroesophageal junction (GEJ).
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks